The KLK7 (SCCE) ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a monoclonal antibody directed against a distinct Antigensic determinant on the intact KLK7 molecule for solid phase immobilization (on the microtiter wells). Standards, calibrators, and patient samples are incubated with the solid phase antibody on the plate. Wells are then washed and incubated with a biotin conjugated anti-KLK7 monoclonal antibody. After a second wash Streptavidin conjugated to HRP is added as a reporting agent. Excess streptavidin-HRP is then washed off and a solution of TMB Reagent is added and incubated resulting in the development of a blue color if KLK7 is present. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of KLK7 is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450nm. Sample Types: serum. Range: 2 - 512 ng/ml. Sensitivity: 2 ng/ml. Time: 2.5 hours ? Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK7 is one of the fifteen kallikrein subfamily members. The KLK7 enzyme is thought to be involved in the proteolysis of intercellular cohesive structures preceding desquamation, which is the shedding of the outermost layer of the epidermis.